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11-beta hydroxysteroid dehydrogenaseCentral obesity is associated with insulin resistance and dyslipidemia. Thus, the mechanisms that control fat
distribution and its impact on systemic metabolism have importance for understanding the risk for diabetes
and cardiovascular disease. Hypercortisolemia at the systemic (Cushing's syndrome) or local levels (due to
adipose-speciﬁc overproduction via 11β-hydroxysteroid dehydrogenase 1) results in the preferential expansion
of central, especially visceral fat depots. At the same time, peripheral subcutaneous depots can become depleted.
The biochemical and molecular mechanisms underlying the depot-speciﬁc actions of glucocorticoids (GCs) on
adipose tissue function remain poorly understood. GCs exert pleiotropic effects on adipocyte metabolic, endo-
crine and immune functions, and dampen adipose tissue inﬂammation. GCs also regulate multiple steps in the
process of adipogenesis. Acting synergistically with insulin, GCs increase the expression of numerous genes
involved in fat deposition. Variable effects of GC on lipolysis are reported, and GC can improve or impair insulin
action depending on the experimental conditions. Thus, the net effect of GC on fat storage appears to depend on
the physiologic context. The preferential effects of GC on visceral adipose tissue have been linked to higher
cortisol production and glucocorticoid receptor expression, but the molecular details of the depot-dependent
actions of GCs are only beginning to be understood. In addition, increasing evidence underlines the importance
of circadian variations in GCs in relationship to the timing of meals for determining their anabolic actions on the
adipocyte. In summary, although the molecular mechanisms remain to be fully elucidated, there is increasing
evidence that GCs have multiple, depot-dependent effects on adipocyte gene expression and metabolism that
promote central fat deposition. This article is part of a Special Issue entitled: Modulation of Adipose Tissue in
Health and Disease.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
Adipose tissue stores excess energy as triglyceride (TG) and re-
leases it as free fatty acids (FFA) depending on body needs. Adipose
tissue is also an endocrine organ that secretes numerous peptide hor-
mones and bioactive molecules that act in auto-, para- and endocrine
fashions to regulate adipose tissue as well as systemic metabolism.
The higher mass of dysfunctional adipose tissue in obesity may cause
or exacerbate metabolic abnormalities that lead to type 2 diabetes,
cardiovascular diseases, and several types of cancer. Adipose tissues or
‘depots’ are found in multiple locations throughout the body. Each has
distinct developmental, structural, and functional features [64]. Visceral
depots (omental andmesenteric) are foundwithin the abdominal cavityion of Adipose Tissue in Health
edicine, Section of Endocrinolo-
ton,MA02118. Tel.:+1 617 638
rights reserved.associated with digestive organs, while subcutaneous (sc) depots are
found under the skin. Fat accumulation in both visceral and abdominal
sc depots confers increased risk for metabolic disease independent of
total body fat, while fat accumulation in the lower body is protective
[64,108]. Similarities betweenmetabolic abnormalities in central obesity
and glucocorticoid (GC) excess, i.e. Cushing's syndrome, have led to the
hypothesis that derangements in GC metabolism and action in adipose
tissue play pivotal roles in the development of obesity and pathogenesis
of obesity related diseases. Indeed, visceral obesity has been appropriately
described as “Cushing's disease of the omentum” [11].
The in vivo effects of GCs are complex. Pathophysiological levels
cause muscle protein breakdown as well as systemic insulin resistance,
while physiological levels are crucial for mobilizing stored fuel for the
“ﬁght orﬂight response” aswell as for replenishing fat storeswhen insu-
lin levels rises with feeding. Most in vivo studies involve administration
of high concentrations of GCs that do not provide insight into howphys-
iological variations in systemic and tissue cortisol levels throughout the
day affect systemic and tissue-speciﬁc metabolism. Additionally, analy-
sis of the in vivo consequences of hypercortisolemia on the adipocytes
is partially confounded by alterations in food intake, compensatory
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[66]. Studies of GC action in vitro are also often difﬁcult to interpret as
they usually involve continuous treatmentwith very high levels of dexa-
methasone (Dex), a type II glucocorticoid receptor (GR) agonist.
GCs have diverse effects on adipose tissue biology. They are
required for induction of lipogenic genes, regulate lipolysis [85] and
adipose endocrine function [9,29,60,63], and play an important role
in restraining adipose tissue inﬂammation in obesity [84]. GCs are
also required for the differentiation of adipocyte precursors [40,80]
and the maintenance of adipogenic genes in cultured adipocytes and
adipose tissue [63,126]. Increasing numbers of studies address the in-
teractions of GC and insulin, and the impact of synergisms between
these twomajor hormones in the regulation of fat distribution and func-
tion in vivo and in vitro.
Here we review available knowledge of the actions of GCs on adi-
pose tissue, attempting to distinguish GC effects on different cell types
that reside within tissues, as well as studies using cell culture models
that examine the direct effects of GCs on the adipocyte. We will brieﬂy
review cellular and molecular mechanisms mediating GC action at
prereceptor and receptor levels, and discuss current understanding of
themechanisms throughwhichGCs affect adiposity and fat distribution.
2. Glucocorticoids promote fat deposition and central adiposity
The powerful effects of GC on adipose tissue accumulation are
clearly demonstrated by early studies showing that adrenalectomy
prevents obesity in Zucker rats and this is reversed by replacement
of corticosterone [28]. In mouse models, overexpression of 11-beta
hydroxysteroid dehydrogenase 1 (HSD1) using an adipose-speciﬁc
promoter (aP2) that produces high local concentration of corticosterone
within adipose tissue results in the preferential expansion of mesenteric
(visceral) fat due to adipocyte hypertrophy [72]. Conversely, genetic or
pharmacological inactivation of HSD1 results in a lean, insulin-sensitive
phenotype [51,53,75].
In humans, excess cortisol at the systemic level results in 2 to 5-fold
increases in central, especially visceral adipose tissues (Cushing's
syndrome), while peripheral sc depots waste [35,93,119]. Although
the clinical literature describes peripheral fat wasting in Cushing's
syndrome, the magnitude of the effect at different sc sites using
whole body imagingmethods and its reversibilitywith treatment remain
poorly documented. One study suggested that expected depot differ-
ences in adipocyte size between the two major sc depots, i.e. smaller
abdominal than gluteo-femoral adipocytes, are lost in Cushing's syn-
drome [91], suggesting hypertrophy of abdominal adipocytes. The prefer-
ential expansion of abdominal sc adipose tissue in Cushing's syndrome is
mediated, at least in part, by elevated activity of lipoprotein lipase (LPL),
the rate-determining step for the hydrolysis and uptake of circulating
TG-fatty acids into adipocytes, together with low lipolytic rates [91]
(also as reviewed in [70]). Additional in vitro as well as in vivo studies
using tracer methodologies are clearly needed to understand how acute
and chronic hypercortisolemia promotes central fat deposition while
wasting peripheral sc depots.
3. Do systemic or local excess glucocorticoids contribute to
central adiposity?
3.1. Systemic cortisol levels are normal in obesity
Individuals under chronic, uncontrollable stress are more likely to
have elevated levels of visceral fat [96]. Despite an increase in overall
cortisol production and rates of turnover, circulating cortisol levels
have been shown to be normal or low in obesity [65,105]. Subsequent
studies revealed abnormalities in the hypothalamus–pituitary–adrenal
(HPA) axis of the obese which are a function of body fat distribution
rather than total fat mass. Repeated measurements of salivary cortisol
in free-living subjects revealed an abnormal diurnal variation of cortisolwhich was positively associated with an upper body fat distribution as
measured by waist-hip ratio (WHR) [96]. This abnormal pattern was
characterized by low variability, absent circadian rhythm, lowmorning
cortisol, and lack of meal-induced cortisol response [65,96,97], all of
which have been associated with long-term over-activation (burn-out)
of the HPA axis. Lower suppression of 8 A.M. cortisol after low dose Dex
is reported among subjects with elevated WHR [65,82], but other stud-
ies show enhanced cortisol suppression after Dex among abdominally
obese subjects [22]. Elevated response to corticotrophin releasing hor-
mone (CRH) stimulation [83], and increased basal [66] and stimulated
response to stress [24] in subjects with abdominal obesity, suggest
over-activation of the HPA axis in these subjects. A recent study [46]
showing active recycling of cortisol in metabolically active tissues high-
lights the difﬁculties of understanding the interactions of central and
peripheral mechanisms that modulate cortisol actions in vivo.
The consequences of the circadian variations in cortisol and inter-
actions with meals for GC action within adipose tissue also deserve
consideration. For example, a pulse of cortisol increases leptin only
when given together with a meal or insulin [56,57]. Indeed GCs are
important for regulating circadian phenomena at the whole body
level. GCs connect the central hypothalamic clock with the peripheral
clocks in multiple tissues, so that diurnal functions are in step with
the environmental cycles of light and nutrition [4]. At the adipocyte
level, supraphysiological doses of GC can acutely affect the expression
and rhythmicity of clock genes [36,124]. Given that genetic disruption
of clock genes speciﬁcally in adipose tissue causes obesity [81], future
studies of how variations in the pattern of cortisol secretion affect re-
gional adipose tissue deposition and function in humans are clearly
needed. GC turnover rates in adipose tissue however, are low and pos-
sibly unaffected by acute ﬂuctuations in circulating cortisol levels [47].
Thus, the local production of GC may be more important in the physio-
logical context, as discussed below (Section 3.2).
3.2. Local production of cortisol is increased in adipose tissue of
obese subjects
While serum cortisol levels are not clearly increased in human
obesity, increased local activation of cortisol from cortisone within
adipose tissue is associated with obesity [23,50,62,88]. Intracellular
cortisol levels are regulated by HSD1 and HSD2. HSD1, a NADPH depen-
dent enzyme, is expressed in many tissues, including liver and adipose
tissue, and acts predominantly as a reductase, generating cortisol in
vivo. HSD2, highly expressed in kidney and colon, inactivates cortisol
to cortisone, protecting the mineralocorticoid receptor (MR) from acti-
vation by cortisol.
HSD1 knockout mice are protected from high-fat diet induced
obesity, hyperglycemia and dyslipidemia [51,53,75], while adipose
overexpression of HSD1 results in obesity with metabolic syn-
drome [72]. HSD1 overexpression or knockout preferentially affects
intraabdominal, especially mesenteric fat, in mouse [72,75]. Simi-
larly, administration of an HSD1 inhibitor at a dose that does not
affect food intake induces preferential loss of mesenteric fat in
mice [7]. The HSD1 knockout mouse also exhibits depot- and diet-
dependent effects on adipose inﬂammation [120]. It will be important
to understand how the ﬁne tuning of intracellular cortisol production
in speciﬁc adipose depots impacts inﬂammation and metabolism in
obesity.
In humans, most but not all studies that examined the relationship
of obesity to adipose HSD1 mRNA and reductase activity show positive
correlations with BMI and adipocyte size [23,50,62,88,111]. It is not
clear however, whether high adipose HSD1 expression is a cause of or
a compensatory mechanism in human obesity. It has been postulated
that higher cortisol synthesis in visceral fat contributes to the preferen-
tial expansion of this depot. Consistent with this idea, one study found
higher HSD1 reductase activity in stromal cell cultures derived from
omental than abdominal sc adipose tissue [10]. Contradictory results
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reported [62,111] and thus, it is not clear whether increased local pro-
duction of cortisol contributes signiﬁcantly to visceral fat accumulation.
Studies of human adipose tissue in organ culture showed that Dex
causes a depot-speciﬁc feed-forward upregulation of HSD reductase ac-
tivity in omental but not abdominal sc adipose tissue [62], suggesting a
mechanism through which GC promote visceral obesity in response to
stress.
HSD2 is reportedly expressed in non-adipocyte cell populations
within human adipose tissues. While HSD2 expression level or its
activity is not increased in obesity, several studies found that HSD2
expression levels are higher in omental than in sc adipose tissue
[62,116], suggesting higher cortisol turnover in the visceral depot.
The higher rate of turnover may provide a mechanism to ﬁne tune
GC production and hence actions in this depot in response to nutrient
or hormonal cues. Potential variations in local GC levels throughout
the day and possible variationswithmeals have not yet been systemical-
ly studied. In this context, it is noteworthy that most studies of cortisol
production and action in adipose tissue are conducted in the overnight
fasted state. Basu et al. [5] found that meal induced cortisol production
and that was due to extrasplanchnic tissue production. Studies of
tissue-speciﬁc meal-induced changes in the prereceptor metabolism of
GCs and their receptor-mediated actions will be important in under-
standing the complex physiology of this hormone in the context of obe-
sity, overnutrition and the metabolic syndrome.
4. Molecular mechanisms governing glucocorticoid actions
on adipocytes
4.1. Role of the type II glucocorticoid receptor
The action of GCs on target cells is thought to be mediated by the
type 2 glucocorticoid receptor (GR,NR3C1), amember of the nuclear re-
ceptor superfamily that is expressed in virtually all tissues. Unliganded
GR resides in the cytoplasm as a heterocomplexwith several heat shock
proteins and chaperone complexes [76]. Ligand binding triggers confor-
mational changes in the receptor that result in dissociation from the
heterocomplex and translocation into the nucleus. The GR homodimer
binds to speciﬁc DNA locations, glucocorticoid response elements
(GREs), and stimulates target gene expression. GR also associates with
less well-deﬁned negative GREs and transrepresses gene transcription.
Once bound to the GREs, conformational changes in the receptor lead
to chromatin remodeling and recruitment of cofactors and the tran-
scriptional machinery.
GR is known to interact with other transcription factors through
direct protein–protein interactions, mutually regulating each other's
transcriptional activities. GR interaction with AP-1 and NF-κB is impor-
tant for the GC-mediated transrepression of inﬂammatory cytokines [8]
and its interaction with COUP-TFII is important for GC actions on meta-
bolic gene expression [18]. GR is also known to associate with STAT3
[59], STAT5 [6] and estrogen receptor [17]. In addition, cytoplasmic or
membrane bound GR causes rapid, nongenomic signaling [103], adding
to the complexity of GC–GR mediated actions.
Recent advances in the GR biology demonstrate that multiple
transcriptional (α and β) and translational isoforms (A, B, C1, 2, 3,
and D1, 2, 3) are expressed in cell type or tissue speciﬁc manners [76].
The GRα and β are generated through alternative splicing of exon 9
(9α and 9β). Similar to GRα, GRβ is ubiquitously expressed, but overall
at lower levels than GRα. GRβ acts as dominant negative inhibitor of
GRα and its expression is increased by proinﬂammatory cytokines,
leading to GC resistance [122]. GRβ also exhibits GRα-independent
transcriptional activity [52]. Additional splice variants, GRγ, GR-A, and
GR-P are reported and impact on GC signaling [76]. Cidlowski's group
demonstrated that eight GR protein subtypes are generated from GRα
mRNA by alternative translation initiation [67]. Use of different transla-
tion initiation sites is tissue speciﬁc and thus, relative abundance of eachisoforms differs between tissues. GR isoforms activate both unique and
common genes [67], revealing complexity of GC signaling through GR
translational isoforms. We have detected these translational isoforms
in human adipose tissues (unpublished observation, MJL and SKF).
Their roles inmodulating GC action in adipocytes and other cells within
adipose tissue remain to be elucidated.
GR transcriptional activity is further modulated by post-translational
modiﬁcations. Human GR is phosphorylated on its N-terminus at three
major sites (serine 203, 211 and 226) [48]. The phosphorylation of GR
affects the transcriptional activities of GR by altering ligand- and DNA-
binding afﬁnity and cofactor recruitment. Phosphorylation at serine 211
is ligand dependent and associated with nuclear localization and activa-
tion. Serine 226 is targeted by mitogen activated kinases (MAPKs), and
this mechanism links high levels of inﬂammatory cytokines to GC resis-
tance in a number of disease states [48,107]. It is logical to postulate
that the high inﬂammatory cytokine levels in obese vs. lean adipose
tissues may increase the expression levels of GRβ as well as phosphor-
ylation at serine 226 and lead to GC resistance, but no studies to our
knowledge have addressed this issue.
4.2. Role of the type I glucocorticoid receptor in adipose biology
Recent studies demonstrate that the mineralocorticoid receptor
(MR, NR3C2), a type 1 glucocorticoid receptor, is also expressed in
adipose tissue [44] and plays important roles in adipogenesis and
adipose endocrine function [45,71]. The relative contribution of GC–GR
and GC–MR in a speciﬁc tissue is far less than clear and depends on the
relative abundance of MR and GR, circulating levels of GCs and aldoste-
rone, and local conversion of cortisone-cortisol by HSD1 and HSD2. Cor-
tisol binds to MRwith 10-fold higher afﬁnity than GR [3] and in classical
MR target tissues such as kidney, MR activation by cortisol is spared by
inactivation of cortisol via HSD2. Because circulating levels of aldoste-
rone are 100–1000 times lower than cortisone and HSD2 is expressed
at much lower levels than HSD1 in the adipose tissue [23,62,116], it is
conceivable that high local concentration of cortisol within the adipose
tissue may activate both GR and MR.
MR activation increases while GR activation decreases pro-
inﬂammatory adipokine expression such as interleukin-6 (IL-6)
and plasminogen activator inhibitor 1 [45]. The selective MR antago-
nist eplerenone reduces adipose expression of proinﬂammatory
genes and inﬁltration of macrophages into adipose tissue with im-
provement in insulin sensitivity in obese rodent models [38,43,44].
In contrast, Dex (a selective agonist for GR) decreases proinﬂammatory
cytokine expression in adipose tissue [9,29,63] andmacrophage inﬁltra-
tion into adipose tissue in vivo [84]. Both HSD1 and MR expression
levels are increased in adipose tissue of obesity, while HSD2 and
GR are not [44,62,116]. Thus, the relative contribution of GC–MR
pathway may be increased in obesity and contribute to adipose tissue
inﬂammation.
4.3. Depot dependent actions of glucocorticoids: role of GR and MR
Intraabdominal fat is thought to be more responsive to GCs than sc
adipose tissue, explaining the preferential accumulation of fat in this
depot with chronic GC excess. Accordingly, studies found that GC
binding to tissue homogenates and GR mRNA expression levels are 2 to
4-fold greater in omental than sc adipose tissue [73,86,90,116]. However,
recent developments in our knowledge of GR biology reveal the more
complex nature of GC signaling in adipose tissue. Thus, the relative abun-
dance of GRαmaynot completely explain the depot-differences inGC ac-
tions. Rather, levels of transcriptional and translational GR isoforms, the
phosphorylation status of GR, and expression levels of MR and
GR-interacting partners, are likely to contribute to the depot-dependent
effects of GCs. Inﬂammatory cytokines including TNF increase GRβ ex-
pression [122] and phosphorylation of GRα at serine 226 and decrease
its transcriptional activity [64]. The higher inﬂammatory environment
476 M.-J. Lee et al. / Biochimica et Biophysica Acta 1842 (2014) 473–481in visceral vs. sc may well play a role in depot differences in GC action.
Further, mRNA expression levels of MR are also higher in omental than
sc depot ([44] and our unpublished observation, MJL and SKF). Thus,
we postulate that the relative contribution of the MR compared to the
GR pathway may be ampliﬁed in human visceral adipose tissues.
5. Glucocorticoid actions on adipose tissue function
GCs affect almost every aspect of adipose tissue, including its de-
velopment, metabolism, and endocrine functions (Fig. 1).
5.1. Glucocorticoids and adipogenesis
GCs are required for full differentiation of adipocytes. GC actions
on adipogenesis are explained by their anti-proliferative effects on
preadipocytes [15,40], induction of a key adipogenic transcription factor,
C/EBPbeta, as well as suppression of Pref-1 and Runx2 [110,123,127].
Several differences are noted in the mechanisms through which GCs en-
hance adipogenesis between the twomost commonly usedpreadipocyte
models, 3T3-L1 and primary human preadipocytes. GCs are required for
cell survival during the clonal expansion that precedes terminal differen-
tiation in 3T3-L1 but not in human preadipocytes [110]. GCs sensitize
insulin signaling in human preadipocytes and this ‘priming’ action en-
hances their responses to adipogenic stimuli [109]. In contrast, this
does not occur in 3T3-L1 cells [109], which are less committed to an ad-
ipocyte cell fate compared to human preadipocytes. Whether visceral
and sc preadipocytes are differentially sensitive to this ‘priming’ action
of GC to induce adipogenesis is unknown.
While the proadipogenic effects of GCs are well accepted, whether
their effects are mediated byMR or GR is not clear. Recent studies dem-
onstrate that MR rather than GR is important for the proadipogenic ef-
fects of GCs in 3T3-L1 and mouse and human preadipocytes [13,14,45].
In primary human preadipocytes however, we found contradictory re-
sults. MR is expressed at much lower levels than GR, and RNAi-
mediated suppression of GR but not MR blocked GC-stimulation of
adipogenesis in primary human preadipocytes (unpublished observa-
tion, MJL and SKF). Adipose-speciﬁc GR or MR knockout mouse models
will be able to determine whether MR or GR mediates GC actions on
adipogenesis in vivo.
Depot-dependent actions of GCs on adipogenesis have been impli-
cated in rodent models. Corticosterone administration to rats increases
intraabdominal depots (mesenteric and epididymal) but not sc ones
[12,92]. The appearance of smaller and more numerous adipocytes in
the mesenteric fat after corticosterone administration [12] suggests
that increases in adipose tissue mass occurred through preadipocyte
differentiation rather than adipocyte hypertrophy. Data on humans
are scarce. Whether the preferential increase in visceral depot that is
observed in subjects with Cushing's syndrome [35,119] is due to in-
crease in adipogenesis or hypertrophy of existing adipocytes or both isGlucocortic
Adipogenesis Adipocyte met
• Glucose metabolis
• Lipid metabolism
Lipolysis
ATGL, HSL, MGL
TG synthesis
FAS, ACC, DGAT, LP
• Insulin sensitivity
Fig. 1. Pleiotropic actions of glucocorticoids in adipose tissue. GCs inﬂuence multiple aspe
production. Arrows indicate the direction of reported changes in experiments conducted und
for developing a full understanding of GC action.not known. In addition, whether GCs differentially affect differentiation
of preadipocytes derived from visceral vs. abdominal and limb sc
adipose tissues is also not established. Omental preadipocytes from
females but not males contain lower levels of GR mRNA and GC bind-
ing, potentially contributing to depot, sex-dependent differences in
preadipocyte differentiation [49].
5.2. Glucocorticoid regulation of adipose gene networks
GCs are known to affect up to 20% of adipose expressed genes in
microarray studies [63,126]. GCs induce genes in metabolic pathways
(expressed mainly in adipocytes) while suppressing genes in immune/
inﬂammatory and proapoptotic pathways. As microarray studies can-
not identifywhether GC affected genes are primary or secondary targets
of GR, ChIP-seq technologies have been applied [126]. More than 8840
genome locations are identiﬁed as GR binding regions (GBR) upon
Dex treatment in 3T3-L1 adipocytes.When ChIP-seq data are compared
with transcriptome analysis, 54% of genes that are regulated by 6-h Dex
treatment contain or are located nearby GBRs. There is little overlap
between the GR targets identiﬁed with ChIP-seq between different
cell types [87], underlining the cell type speciﬁc effects of the GC–GR
pathway. The speciﬁcity of GC actions may be determined by the ex-
pression levels of GR isoforms and the phosphorylation state of GR, but
no studies to date have addressed this possibility.
5.3. Glucocorticoids and adipose tissue metabolism
Adipose tissues store excess energy as neutral lipids, TG, and release
it as FFA and glycerol in highly regulated fashion. TG is synthesized from
FFA esteriﬁed to a glyceride–glycerol backbone. The glyceride–glycerol
backbone is derived from glucose and the majority of FFA is delivered
through LPL breakdown of circulating TG in chylomicron or very low
density lipoprotein (VLDL), as de novo lipogenesis (DNL) is minimal
in normal situation [42]. GCs are known to affect almost every aspect
of these adiposemetabolic processes (Fig. 2A). The effects of GCs on ad-
ipocyte glucose metabolism [1] and lipid metabolism [85] have been
previously reviewed so we only brieﬂy discuss them here.
5.3.1. Glucocorticoid effects on adipocyte glucose metabolism
GC treatment in vitro, in the absence of insulin, have been shown
to decrease glucose uptake and metabolism (oxidation into CO2 and
to glyceride-glycerol and FA synthesis) [27,31,37,77] with a time lag
of 1–2 h. In addition, pretreatment with GCs antagonizes the ability
of insulin to stimulate glucose uptake in adipocytes through different
mechanisms depending on the exposure time. Acutely, GCs do not affect
insulin binding, thus short-term effects of GCs might be explained by
glucose transporter translocation [31,77]. Chronic Dex-impairment of
insulin-stimulated glucose uptake is explained through decreases in
insulin binding, expression of insulin receptor and insulin receptoroid
abolism
m
L
Adipokine production
Leptin, SAA, RBP4
IL-6, TNF, CCL2, IL-8
• Produced in stromal cells
Adiponectin
• Produced in adipocytes
cts of adipose tissue biology: adipogenesis, metabolism, inﬂammation and adipokine
er different conditions. Specifying these conditions, as discussed in the text, is essential
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[31,37,77,98,113]. Dex effects on basal glucose uptake however, are
more pronounced than its antagonismof the insulin-stimulated glucose
uptake. Thus, Dex actually increases fold stimulation atmaximal insulin
concentrations [31]. Similarly, enhanced insulin signaling and glucose
uptake following pretreatment with GCs in human adipocytes [32,34]
and preadipocytes [109] have been reported.
GCs also exert depot-dependent effects on insulin signaling, glu-
cose uptake and the expression of insulin signaling proteins [41,69].
GCs increase IRS2 expression and insulin stimulation of AKT phos-
phorylation in abdominal sc but not omental adipocytes [41], while
chronically GCs down-regulate components of the insulin signaling
in omental but not abdominal sc adipose tissue [69].5.3.2. Glucocorticoids and lipid storage, additive or synergistic effects
with insulin to increase lipid synthesis
GCs differentially affect lipid storage depending on nutritional or
hormonal conditions. While GCs decrease lipogenesis and FFA uptake
in basal or fasting conditions [33,118], GCs act additively or synergis-
tically with insulin to upregulate lipogenesis [33,74,121]. GC induc-
tion of DNL is explained by stimulation of key enzymes, acetyl-CoA
carboxylase (ACC) and fatty acid synthase (FAS) [63,121] (Fig. 2A).
DNL in adipose tissue is a minor contributor to total TG-FA [42] in
humans eating moderate fat diets and the majority of FFA is derived
from LPL-mediated breakdown of circulating TG-rich lipoproteins.
GCs induce adipose LPL mRNA expression and activity and enzymesTG
FFA
hypertrophy
high systemic FFA
GC ⊕ ⊕
B
FFA
CM
VLDL FFA
Glycer
FFA
LPL
Glycerol
FFA
LIP
glucose G
G3P
?
GLUT1&4
pyruv
lactat
ACC
FAS
A
Fig. 2. Glucocorticoids simultaneously increase pathways of TG synthesis and breakdown. A
the expression of genes involved in lipid uptake (LPL), TG synthesis (LIPIN, AGPAT, and DGA
volved in TG hydrolysis (ATGL, HSL, and MGL). GC induction of PCK1 expression is likely to
lipid turnover in adipose tissue. While GCs are widely cited as lipolytic and thought to incre
balance toward TG synthesis in a depot-dependent manner may lead to hypertrophy of exiof TG synthesis with greater effects in omental than abdominal sc
[2,30,63,79], and this mechanism may contribute to the hypertrophy of
omental adipocytes with excess GCs. The sensitivity and responsiveness
of different sc depots, i.e. abdominal vs. gluteo-femoral, to GCs have not
been studied, but may contribute to variations in fat distribution.5.3.3. Glucocorticoids and lipolysis
GCs are widely cited as being lipolytic. However, results differ
depending on the concentration and duration of treatment and the
experimental model systems used. Although infusion of fairly high
concentrations of GCs increases systemic FFA and glycerol within sever-
al hours in overnight fasted humans [19–21,41,99,100], cortisol infusion
actually decreases abdominal sc adipose tissue lipolysis asmeasured by
the arterio-venous difference across this depot [99]. The authors sug-
gested that depot-speciﬁc effect of cortisol on the enzymes of intra-
cellular lipolysis (hormone-sensitive lipase, HSL) and intravascular
lipolysis (LPL)may explain how cortisol could acutely increase systemic
lipolysis (glycerol and FA rate of appearance) while chronically higher
levels would promote net central fat deposition over the long-term. A
recent study demonstrated that systemic hydrocortisone infusion in-
creases lipolysis, but themagnitude of suppression by insulin is actually
increased [41].
Analysis of data from long-term (days to weeks) infusion of GCs
[12,114,125,126] is complicated by compensatory hyperinsulinemia
whichmay chronically promote higher FA ﬂux via induction of insulin
resistance and activation of the sympathetic nervous system. In addition,GC
TG
DG
MG
ol
ATGL
HSL
MGL
IN
AGPAT
DGAT1
ate
e
PCK1
. GCs especially when added in the presence of insulin, mimicking the fed state, induce
T1) and de novo lipogenesis (ACC, FAS). GCs also increase the expression of genes in-
play a role in glyceroneogenesis, contributing to TG synthetic pathway. B. GCs increase
ase systemic FFA, they also increase lipid uptake and TG synthesis. Factors that tip this
sting adipocytes and hence affect regional adiposity.
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beta-adrenergic agonists [55,58,68,94] also contribute to high lipolysis
after chronic GC treatment.
Results from in vitro studies testing the effects of GCs on lipolysis
using adipocytes and adipose tissue in culture are conﬂicting. In 3T3-L1
adipocytes and rat adipocytes, GCs increase lipolysis [12,125]. Adipocytes
isolated after in vivo GC treatment also exhibit higher rates of lipolysis in
vitro [12,54]. The stimulatory effects of GCs on lipolysis have been attrib-
uted to its induction of adipose triglyceride lipase (ATGL) and HSL, and
down-regulation of phosphodiesterase 3B (PDE3B) [12,54,125]. In
contrast, we did not ﬁnd any signiﬁcant effects of GC (Dex) on lipol-
ysis in primary cultures of newly-differentiated human adipocytes
[61]. In human adipose tissue explants, GCs do not affect [26], inhibit
[78], or antagonize insulin-stimulated lipolysis ([16] and our unpublished
observation, MJL and SKF).
GCs have permissive effects on growth hormone (GH) and cate-
cholamines to increase lipolysis. The permissive effects of GCs on
GH action are demonstrated in vivo [21], in rat adipocytes [27], and
in human adipose tissue [26,78]. GCs are also required for normal re-
sponse to catecholamine or fasting induction of lipolysis [25]. Similarly,
in primary human adipocytes, we found that Dex enhances responses to
beta-adrenergic stimulation [61].
Several studies showed that chronic exposure of human adipose
tissue and 3T3-L1 adipocytes or mice in vivo to GCs increases genes
involved in lipid storage and mobilization simultaneously [26,63,126].
Recently, Hellerstein's group demonstrated that increased cycling be-
tween TG and FFAs in adipose tissues of Cushingoid CRH-Tg mice in
vivo [39]. Thus, it appears that GCs, at least in long-term, increase lipid
turnover in adipose tissue (Fig. 2B). Factors that tip the balance toward
TG synthesis over breakdownmay promote the hypertrophy of existing
adipocytes in a depot-dependent manner and hence affect regional
adiposity.
5.4. Glucocorticoid modulation of adipose endocrine function
Adipose tissue secretes numerous peptide hormones and cyto-
kines. The adipocytes themselves produce many of these, including
leptin, adiponectin, retinol binding protein 4 (RBP4), and serum amyloid
A (SAA), while most proinﬂammatory cytokines and chemokines are
produced by non-adipose cells within the adipose tissue [112]. GCs reg-
ulate the production ofmany of these adipokines. GCs increase leptin ex-
pression [60], while their effects on adiponectin are still controversial
[106]. As expected from their well known anti-inﬂammatory actions,
GCs decrease inﬂammatory cytokines, namely IL-6, IL-8, and TNF in in-
tact samples of adipose tissue [9,29]. Accordingly, the most signiﬁcantly
suppressed pathway after Dex treatment in human adipose tissue is
immune/inﬂammatory responses [63]. Dex however, induces some
immune/inﬂammatory genes that are known to be involved in acute
phase response or innate immunity (SAA, Complement factor 7, 1q,
andD, RBP4, andmetallothioneins).Many of theseDex-induced immune
genes are expressed in mature adipocytes, while suppressed genes are
mainly expressed in stromal cells [112], demonstrating cell type speciﬁc
effects of Dex within adipose tissue.
6. Glucocorticoids and brown adipose tissue
Metabolically active brown adipose tissue is believed to be present
in adult humans and may play a role in energy homeostasis and weight
control [89]. While GCs promote brown preadipocyte differentiation
[101], they inhibit uncoupling protein 1 (UCP1) expression and activity
in brown adipocytes [102,117]. Accordingly, corticosterone administra-
tion to rats decreases thermogenic activity and UCP1 expression while
increasing lipid accumulation in brown adipose tissue [104]. These
data demonstrate that GCs impair brown adipose tissue function and
promote a ‘brown’ to ‘white’ phenotypic conversion.7. Glucocorticoid regulated pathways as therapeutic targets
GCs are widely prescribed due to their anti-inﬂammatory or immu-
nosuppressive effects. Chronic GCs, however, result in weight gain,
hypertension and increased risk for diabetes. GC-transactivated genes
are implicated in the pathogenesis of such side effects,while GR interac-
tions with AP-1 and NF-κB are important in its anti-inﬂammatory
actions. Thus, selective GR modulators that favor transrepression over
transactivation are in development [115]. In addition, clinical trials test-
ing the effectiveness of HSD1 inhibitors for the treatment for obesity
and metabolic diseases are under investigation [95].
8. Conclusion
GCs have profound effects on adipose tissue, adipogenesis and ad-
ipose tissue metabolic and endocrine functions. With chronic excess
GCs, produced systemically or through local adipose tissue conversion,
fat accumulates in central adipose depots and contributes to metabolic
derangements. The mechanisms through which high GCs promote the
preferential expansion of visceral adipose depots remain incompletely
understood. Intraabdominal depots are thought to be more responsive
to GCs at least in part due to high GR expression, leading to expansion
of this depot. In addition, the type 1 glucocorticoid receptor, MR is
expressed in adipose tissue, and mediates several actions of GCs. The
molecular complexity in GR biology in adipocytes, speciﬁcally the
roles of multiple GR isoforms, interactions of GR with other tran-
scription factors in adipocytes are emerging. The cross-talk of GR
and inﬂammatory pathways via post-translational modiﬁcations of
GR is beginning to be understood and holds promise for the develop-
ment of novel therapies for abdominal obesity and its deleterious met-
abolic consequences.
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